2m 2m 2m 2m 2m 2m 2m
Cannabis Global (CBGL)
OTC
$0.0001$0.00 (0.00%)
Price as of Jun 03, 2026- $656,419.00Market Cap
- 9,900.00%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Cannabis Global (CBGL)
$0.0001$0.00 (0.00%)
Annual
Quarterly
08/31/2021 | 08/31/2020 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 1.6M +5,828.89% | 27,004 N/A | |
Cost of Revenue | 1.4M +5,677.82% | 24,521 N/A | |
Gross Profit | 184,258 +7,320.78% | 2,483 N/A | |
Sales and Marketing Expense | 64,667 -69.68% | 213,302 N/A | |
Research and Development Expense | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | 45,482 +1,260.92% | 3,342 N/A | |
Total Operating Expenses | 2.1M -41.31% | 3.6M N/A | |
Operating Profit | -1.9M -46.36% | -3.6M N/A | |
Interest Income | -55,435 N/A | N/A N/A | |
Interest Expense | -7.4M +422.85% | -1.4M N/A | |
Interest Income and Expense and Net | -7.5M +426.74% | -1.4M N/A | |
Total Nonoperating Income and Expense | -6.2M +372.79% | -1.3M N/A | |
Income before Taxes | -1.9M -46.36% | -3.6M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | 0 N/A | |
Net Income | -7.8M +58.94% | -4.9M N/A | |
Net Income from Continuing Operations Applicable to Common | -7.8M +58.94% | -4.9M N/A | |
Basic EPS and Net Income | -0.13 -55.17% | -0.29 N/A | |
Diluted EPS and Net Income | -0.13 -55.17% | -0.29 N/A | |
Basic Weighted Average Shares | 58.3M +240.84% | 17.1M N/A | |
Diluted Weighted Average Shares | 58.3M +240.84% | 17.1M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 30,813 +1,217.92% | 2,338 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 30,813 +1,217.92% | 2,338 N/A | |
Total Current Assets | 442,065 +469.11% | 77,676 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 218,535 +760.17% | 25,406 N/A | |
Total Long-Term Assets | 218,535 +760.17% | 25,406 N/A | |
Total Assets | 11.3M +387.65% | 2.3M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 2.7M +13.96% | 2.4M N/A | |
Total Current Liabilities | 8.7M +132.61% | 3.8M N/A | |
Total Long-Term Debt | 672,794 +1,245.59% | 50,000 N/A | |
Total Long-Term Liabilities | 1.2M +9.77% | 1.1M N/A | |
Total Liabilities | 10.0M +165.47% | 3.8M N/A | |
Retained Earnings | -13.9M +129.35% | -6.1M N/A | |
Total Stockholders Equity | -2.2M +54.14% | -1.4M N/A | |
Total Shares Outstanding | 84.9M +213.64% | 27.1M N/A | |
Cash Flow | |||
Cash from Operating Activities | -1.5M -3.36% | -1.5M N/A | |
Capital Expenditures | 9,511 -38.63% | 15,499 N/A | |
Cash from Investing Activities | -7,311 -52.83% | -15,499 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 1.5M +8.57% | 1.4M N/A | |
Financials Ratio | |||
Gross Margin | 11.51% +25.16% | 9.19% N/A | |
Operating Margin | -121.42% -99.10% | -13,419.83% N/A | |
Return on Assets | -114.68% -70.45% | -388.14% N/A | |
Return on Equity | 429.59% -40.13% | 717.59% N/A | |
Revenue Growth | 5,828.89% N/A | N/A N/A | |
Current Ratio | 0.05 +143.96% | 0.02 N/A | |
Cash Ratio | 0.004 +483.33% | 0.0006 N/A | |
Debt-to-Equity Ratio | -1.52 -9.54% | -1.68 N/A | |
Debt-to-Assets Ratio | 0.30 -71.41% | 1.04 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow